DK0839525T3 - Præparat med forlænget frigivelse - Google Patents

Præparat med forlænget frigivelse

Info

Publication number
DK0839525T3
DK0839525T3 DK97308692T DK97308692T DK0839525T3 DK 0839525 T3 DK0839525 T3 DK 0839525T3 DK 97308692 T DK97308692 T DK 97308692T DK 97308692 T DK97308692 T DK 97308692T DK 0839525 T3 DK0839525 T3 DK 0839525T3
Authority
DK
Denmark
Prior art keywords
release preparation
active substance
physiologically active
extended release
sustained
Prior art date
Application number
DK97308692T
Other languages
Danish (da)
English (en)
Inventor
Hiroaki Okada
Yayoi Douken
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of DK0839525T3 publication Critical patent/DK0839525T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK97308692T 1996-10-31 1997-10-30 Præparat med forlænget frigivelse DK0839525T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29044196 1996-10-31
EP97308692A EP0839525B1 (en) 1996-10-31 1997-10-30 Sustained-release preparation

Publications (1)

Publication Number Publication Date
DK0839525T3 true DK0839525T3 (da) 2004-11-29

Family

ID=17756079

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97308692T DK0839525T3 (da) 1996-10-31 1997-10-30 Præparat med forlænget frigivelse

Country Status (9)

Country Link
US (2) US6113943A (ja)
EP (1) EP0839525B1 (ja)
JP (1) JP4361144B2 (ja)
AT (1) ATE272394T1 (ja)
CA (1) CA2219698C (ja)
DE (1) DE69730093T2 (ja)
DK (1) DK0839525T3 (ja)
ES (1) ES2221019T3 (ja)
PT (1) PT839525E (ja)

Families Citing this family (347)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
EP0998940A1 (en) * 1998-09-30 2000-05-10 Laboratoire Theramex Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of LH-RH analogues
KR100584634B1 (ko) 1998-12-15 2006-05-30 다케다 야쿠힌 고교 가부시키가이샤 폴리머의 제조방법
EP1161257A2 (en) 1999-03-17 2001-12-12 Novartis AG Pharmaceutical compositions comprising tgf-beta
SK342002A3 (en) 1999-07-15 2002-05-09 Takeda Chemical Industries Ltd Sustained release compositions, process for producing the same and use thereof
US6303138B1 (en) * 1999-09-17 2001-10-16 Depuy Orthopaedics Endothelin-based compositions for enhancing connective tissue repair
DK1274459T3 (da) 2000-04-19 2006-02-06 Genentech Inc Præparater med vedholdende frigivelse indeholdende væksthormon
ATE425776T1 (de) * 2000-04-28 2009-04-15 Fziomed Inc Haemostatische zusammenstellung von polysauren und polyalkylenoxyden und deren verwendungsmethoden
US20050042194A1 (en) * 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
JP2002003406A (ja) * 2000-06-21 2002-01-09 Sankyo Co Ltd 脳血管攣縮予防製剤
JP5046447B2 (ja) * 2000-08-07 2012-10-10 和光純薬工業株式会社 乳酸重合体及びその製造方法
ATE375145T1 (de) 2000-12-21 2007-10-15 Alrise Biosystems Gmbh Induziertes phasenübergangs verfahren zur herstellung von hydrophile wirkstoffe enthaltende mikropartikeln
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
DK1372729T3 (da) * 2001-02-23 2009-06-22 Genentech Inc Nedbrydelige polymere til injektion
US6558702B2 (en) * 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
EP1382350A4 (en) * 2001-04-25 2006-01-04 Takeda Pharmaceutical MEANS AGAINST THE PROPHYLAXIS BEFORE POSTOPERATIVE REPEAT OF PREMOPEOPAUSAL BREAST CANCER
WO2003000282A1 (en) * 2001-06-21 2003-01-03 Genentech, Inc. Sustained release formulation
AR034641A1 (es) 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla
GB0122113D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Composition
AU2002362039B2 (en) * 2001-12-03 2007-07-26 Soligenix, Inc Stabilized reverse micelle compositions and uses thereof
JP2003192773A (ja) * 2001-12-26 2003-07-09 Mitsui Chemicals Inc 生体吸収性ポリヒドロキシカルボン酸及びその製造法
WO2003075958A1 (fr) * 2002-03-11 2003-09-18 Takeda Chemical Industries, Ltd. Medicaments permettant de traiter une maladie dependant d'une hormone sexuelle
DK1532985T3 (en) 2002-06-25 2016-12-05 Takeda Pharmaceuticals Co PROCEDURE FOR PREPARING A COMPOSITION WITH LONG-TERM RELEASE
JP2007525429A (ja) * 2003-03-11 2007-09-06 キューエルティー ユーエスエー，インコーポレイテッド． 細胞スケジュール依存性抗癌剤のための処方
JP4898431B2 (ja) * 2003-04-29 2012-03-14 ザ ジェネラル ホスピタル コーポレイション 複数薬物の持続放出のための方法およびデバイス
US20040244806A1 (en) * 2003-06-09 2004-12-09 Ferree Bret A. Treating disc herniation and other conditions with leukocytes
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
AP1899A (en) 2003-08-08 2008-10-10 Biovail Lab Int Srl Modified-release tablet of bupropion hydrochloride
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US8846069B2 (en) * 2003-11-20 2014-09-30 Abbott Cardiovascular Systems Inc. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
US20050112170A1 (en) * 2003-11-20 2005-05-26 Hossainy Syed F. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20060094651A1 (en) * 2004-11-03 2006-05-04 Cyrus Karkaria Formulations and methods of production of FGF-20
EP1768650B1 (en) 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
WO2005122734A2 (en) * 2004-06-14 2005-12-29 The Research Foundation Of State University Of New York Nanosphere/microsphere delivery system for the treatment of spinal cord injury
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
US20060039890A1 (en) * 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
AU2005294382A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
DE602005026998D1 (de) * 2005-01-14 2011-04-28 Camurus Ab Somatostatin-analog-formulierungen
ES2343641T3 (es) 2005-01-14 2010-08-05 Camurus Ab Formulaciones bioadhesivas topicas.
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
EP1843751B1 (en) 2005-01-21 2020-09-30 Camurus Ab Pharmaceutical lipid compositions
WO2006130217A2 (en) * 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates
ATE534652T1 (de) 2005-04-01 2011-12-15 Univ California Phosphono-pent-2-en-1-yl-nukleoside und analoga
ATE382337T1 (de) * 2005-04-28 2008-01-15 Nipro Corp Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer
DK1888031T3 (da) * 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
JPWO2007029361A1 (ja) * 2005-09-02 2009-03-12 武田薬品工業株式会社 短鎖デオキシリボ核酸又は短鎖リボ核酸含有徐放性マイクロスフェア及びその製造法
DK1787658T3 (da) 2005-11-10 2012-06-25 Chemi Spa Formuleringer med forsinket frigørelse og indeholdende somatostatin-analoge væksthormoninhibitorer
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
CN101404981A (zh) * 2006-03-13 2009-04-08 恩希赛弗制药公司 治疗舒张性心力衰竭的方法和组合物
MX2008011633A (es) 2006-03-13 2008-12-16 Activx Biosciences Inc Aminoquinolonas como inhibidores de gsk-3.
MX2008011844A (es) * 2006-03-13 2008-10-02 Encysive Pharmaceuticals Inc Formulaciones de sitaxsentano de sodio.
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
DK2066662T3 (da) 2006-09-21 2013-01-07 Kyorin Seiyaku Kk Serinhydrolaseinhibitorer
CN101687788A (zh) 2006-10-19 2010-03-31 奥斯拜客斯制药有限公司 取代的吲哚
US20100137421A1 (en) * 2006-11-08 2010-06-03 Emmanuel Theodorakis Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
US7713541B1 (en) 2006-11-21 2010-05-11 Abbott Cardiovascular Systems Inc. Zwitterionic terpolymers, method of making and use on medical devices
GEP20125597B (en) 2006-12-18 2012-08-10 Takeda Pharmaceutical Sustained-release composition and production method thereof
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
KR20090086115A (ko) * 2006-12-22 2009-08-10 엔싸이시브 파마슈티칼즈 인코퍼레이티드 Ｃ３ａ 수용체의 조정제 및 이의 사용 방법
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
PT2144604E (pt) 2007-02-28 2011-10-19 Conatus Pharmaceuticals Inc Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
AR065728A1 (es) 2007-03-15 2009-06-24 Auspex Pharmaceuticals Inc Fenetilaminas sustituidas con actividad de serotoninergico y/o norepinefrinergico
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
AU2008274941A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
KR101563018B1 (ko) * 2007-09-11 2015-10-23 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-３ 억제제로서의 시아노아미노퀴놀론 및 테트라졸로아미노퀴놀론
JP5373799B2 (ja) 2007-09-12 2013-12-18 杏林製薬株式会社 Ｇｓｋ−３阻害剤としてのスピロ環式アミノキノロン
EP2052716B1 (en) 2007-10-24 2014-12-31 Camurus AB Controlled release formulations
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DK2947072T3 (en) 2008-03-17 2017-01-23 Ambit Biosciences Corp 1- (3- (6,7-DIMETHOXYQUINAZOLIN-4-YLOXY) PHENYL) -3- (5- (1,1,1-TRIFLUOR-2-METHYLPROPAN-2-YL) ISOXAZOL-3-YL) UREA AS RAF CHINESE MODULATOR IN TREATMENT OF CANCER DISEASES
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
MX2010012514A (es) * 2008-05-20 2011-05-30 Cerenis Therapeutics S A Niacina y un medicamento nsaid para tratamiento combinado.
BRPI0913677A2 (pt) 2008-07-02 2015-12-15 Idenix Pharmaceuticals Inc composto, metabólito purificado, método para tratar um hospedeiro infectado com um vírus flaviviridade, composição farmacêutica, método para preparar o composto purificado, e, processo para preparar o composto
EP2315571A4 (en) * 2008-07-16 2013-05-01 Surmodics Pharmaceuticals Inc METHOD FOR PRODUCING MICROPARTICLES WITH BIOACTIVE PEPTIDES
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
US20100152227A1 (en) * 2008-12-11 2010-06-17 A.P. Pharma, Inc. Methods for Enhancing Stability of Polyorthoesters and Their Formulations
WO2010076329A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
EP2601934A1 (en) 2009-01-22 2013-06-12 Ludwig-Maximilians-Universität München Vesicular phospholipid gels comprising proteinaceous substances
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
CN105837560A (zh) 2009-02-27 2016-08-10 埃姆比特生物科学公司 调控jak激酶的喹唑啉衍生物和其使用方法
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
JP2012520314A (ja) 2009-03-11 2012-09-06 アムビト ビオスシエンセス コルポラチオン 癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
AU2010221990B2 (en) * 2009-03-11 2015-06-04 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as GSK-3 inhibitors
AR075974A1 (es) 2009-03-27 2011-05-11 Pathway Therapeutics Ltd Pirimidinil y 1,3,5-triazinilbencimidazolsulfonamidas y su uso en terapia del cancer
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
CN102459210B (zh) 2009-04-22 2015-09-02 埃克希金医药品有限公司 芳基磺酰胺ccr3拮抗剂
TW201041583A (en) 2009-04-22 2010-12-01 Axikin Pharmaceuticals Inc 2,5-disubstituted arylsulfonamide CCR3 antagonists
HUE038507T2 (hu) 2009-04-22 2018-10-29 Sma Therapeutics Inc 2,5-diszubsztituált arilszulfonamid CCR3-antagonisták
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
EP2451802A1 (en) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
US8496973B2 (en) 2009-07-08 2013-07-30 Hope Medical Enterprises, Inc. Sodium thiosulfate-containing pharmaceutical compositions
EP2467144A1 (en) 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
BR112012003661A2 (pt) 2009-08-19 2017-04-25 Ambit Biosciences Corp "compostos de biarila e métodos de uso dos mesmos."
WO2011056566A2 (en) 2009-10-26 2011-05-12 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
MY159958A (en) 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
SG181896A1 (en) * 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
WO2011082289A1 (en) 2009-12-30 2011-07-07 Scynexis Inc. Cyclosporine analogues
WO2011089167A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
ES2632548T3 (es) 2010-02-05 2017-09-14 Tragara Pharmaceuticals, Inc. Formas de estado sólido de los inhibidores de la quinasa macrocíclica
LT3202460T (lt) 2010-02-11 2019-10-10 Celgene Corporation Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
AU2011223873B2 (en) 2010-03-02 2015-06-25 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
MX336559B (es) 2010-03-17 2016-01-25 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida.
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
EP2585063A1 (en) 2010-06-01 2013-05-01 Biotheryx Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
MX2012013879A (es) 2010-06-01 2013-04-03 Biotheryx Inc Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
JP5855095B2 (ja) 2010-06-07 2016-02-09 ノボメディックス，エルエルシーＮｏｖｏｍｅｄｉｘ，Ｌｌｃ フラニル化合物およびその使用
US20140200270A1 (en) 2013-01-11 2014-07-17 Summa Health System Vitamins c and k for treating polycystic diseases
AU2011279808B2 (en) 2010-07-19 2015-07-02 Mayo Foundation For Medical Education And Research (Mfmer) Vitamin C and chromium-free vitamin K, and compositions thereof for treating an NFKB-mediated condition or disease
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
CA2809983A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
US20130303533A1 (en) 2010-09-01 2013-11-14 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
MX2013002384A (es) 2010-09-01 2013-07-05 Ambit Biosciences Corp Compuestos quinazolina y metodos para utilizarlos.
WO2012030914A1 (en) 2010-09-01 2012-03-08 Ambit Boisciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
EP2611795B1 (en) 2010-09-01 2016-05-04 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
US20120053176A1 (en) 2010-09-01 2012-03-01 Ambit Biosciences Corp. Adenosine a3 receptor modulating compounds and methods of use thereof
WO2012030910A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
US20130317045A1 (en) 2010-09-01 2013-11-28 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
EP2627635A1 (en) 2010-10-11 2013-08-21 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
EP2670396A1 (en) 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
AU2012212066A1 (en) 2011-02-03 2013-08-15 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
AR085651A1 (es) 2011-03-11 2013-10-16 Celgene Corp Metodos para tratar cancer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
EP2691384B1 (en) 2011-03-28 2016-10-26 MEI Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
CA2831590A1 (en) 2011-03-28 2012-10-04 Mei Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
EP2691388A1 (en) 2011-03-28 2014-02-05 MEI Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
KR20140042868A (ko) 2011-06-23 2014-04-07 맵 파마슈티컬스, 인코포레이티드 신규한 플루오로에르골린 유사체
WO2013003157A1 (en) 2011-06-28 2013-01-03 Yale University Cell-free tissued engineered vascular grafts
CN103946226A (zh) 2011-07-19 2014-07-23 无限药品股份有限公司 杂环化合物及其应用
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013039920A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
EP2768838A1 (en) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
PT2766359T (pt) 2011-10-14 2016-07-14 Ambit Biosciences Corp Compostos heterocíclicos e utilização dos mesmos como moduladores de recetores tirosina-cinase de tipo iii
US8586527B2 (en) 2011-10-20 2013-11-19 Jaipal Singh Cerivastatin to treat pulmonary disorders
BR112014013693B1 (pt) 2011-12-05 2023-01-31 Camurus Ab Pré-formulação, e, uso de uma pré-formulação
SG10201509139QA (en) 2011-12-19 2015-12-30 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
SG11201403433PA (en) 2011-12-21 2014-07-30 Map Pharmaceuticals Inc Novel neuromodulatory compounds
PL2806877T3 (pl) 2012-01-23 2020-06-01 Sage Therapeutics, Inc. Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny
US9611253B2 (en) 2012-02-29 2017-04-04 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
AU2013205306B2 (en) 2012-03-16 2015-09-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
AP3913A (en) 2012-05-22 2016-11-26 Idenix Pharamaceuticals Inc D-amino acid compounds for liver disease
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
MX350964B (es) 2012-05-25 2017-09-27 Camurus Ab Formulaciones de agonistas del receptor de somatostatina.
US9957247B2 (en) 2012-06-07 2018-05-01 Georgia State University Research Foundation, Inc. SecA inhibitors and methods of making and using thereof
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
EP2877155B1 (en) 2012-07-26 2020-10-28 Camurus AB Opioid formulations
SI2882441T1 (sl) 2012-08-09 2020-08-31 Celgene Corporation Zdravljenje bolezni v zvezi z imunskim sistemom in vnetnih bolezni
TW201408657A (zh) 2012-08-09 2014-03-01 Celgene Corp （ｓ）－３－（４－（（４－（嗎啉基甲基）苄基）氧基）－１－氧異吲哚啉－２－基）哌啶－２，６－二酮之鹽及固態形式、包含其之組合物及其使用方法
EP3957309A1 (en) 2012-08-21 2022-02-23 Sage Therapeutics, Inc. Preparation of a composition comprising allopregnanolone and sulfobutylether-beta-cyclodextrin
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
EP2892884A1 (en) 2012-09-07 2015-07-15 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide ccr3 antagonists
LT2900230T (lt) 2012-09-27 2019-01-10 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
PE20151318A1 (es) 2012-10-08 2015-10-03 Idenix Pharmaceuticals Inc Analogos de 2'-cloro nucleosido para infeccion por vhc
WO2014063019A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
NZ744567A (en) 2012-11-01 2020-03-27 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
CA2890177A1 (en) 2012-11-08 2014-05-15 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
KR102180342B1 (ko) 2012-11-30 2020-11-18 노보메딕스 엘엘씨 치환된 바이아릴 설폰아미드 및 이의 용도
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
BR112015014964A2 (pt) 2012-12-21 2017-07-11 Map Pharmaceuticals Inc novos derivados de metisergida
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
BR112015029969A2 (pt) 2013-05-30 2017-07-25 Infinity Pharmaceuticals Inc tratamento de câncer usando moduladores de isoformas quinase pi3
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
WO2015031613A1 (en) 2013-08-30 2015-03-05 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015051336A1 (en) 2013-10-03 2015-04-09 David Wise Compositions and methods for treating pelvic pain and other conditions
JP6466924B2 (ja) 2013-10-04 2019-02-06 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
EP3063165A1 (en) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
TR201901299T4 (tr) 2013-11-26 2019-02-21 Childrens Medical Ct Corp Obezite tedavisine yönelik bileşikler ve bunların kullanım yöntemleri.
US10030044B2 (en) 2013-11-27 2018-07-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
US20170198005A1 (en) 2013-11-27 2017-07-13 Idenix Pharmaceuticals Llc 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
EP3083654A1 (en) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or nucleosides for the treatment of hcv
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2741914C2 (ru) 2014-03-20 2021-01-29 Капелла Терапьютикс, Инк. Производные бензимидазола как ингибиторы тирозинкиназ erbb для лечения рака
WO2015143161A1 (en) 2014-03-20 2015-09-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
WO2015157559A2 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins for the treatment of pain
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
RU2016148364A (ru) 2014-05-12 2018-06-13 Конатус Фармасьютикалз, Инк. Лечение осложнений хронического заболевания печени
JP2017516779A (ja) 2014-05-28 2017-06-22 アイデニクス・ファーマシューティカルズ・エルエルシー 癌治療のためのヌクレオシド誘導体
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
PE20170268A1 (es) 2014-06-19 2017-04-21 Ariad Pharma Inc Compuestos de heteroarilo para la inhibicion de cinasa
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
MX2017003215A (es) 2014-09-12 2018-01-24 Tobira Therapeutics Inc Terapia de combinacion con cenicriviroc para el tratamiento de la fibrosis.
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CN111888368B (zh) 2014-10-21 2024-02-02 武田药品工业株式会社 5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的晶形
EP3209658A1 (en) 2014-10-24 2017-08-30 Biogen MA Inc. Diterpenoid derivatives and methods of use thereof
AU2015369690B2 (en) 2014-12-23 2019-01-17 SMA Therapeutics Inc. 3,5-diaminopyrazole kinase inhibitors
MX2017009406A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo isoergolina y usos de estos.
AU2016209492B2 (en) 2015-01-20 2020-10-22 Xoc Pharmaceuticals, Inc Ergoline compounds and uses thereof
EP3303361A1 (en) 2015-05-27 2018-04-11 Idenix Pharmaceuticals LLC Nucleotides for the treatment of cancer
AU2016282790B9 (en) 2015-06-23 2020-01-30 Neurocrine Biosciences, Inc. VMAT2 inhibitors for treating neurological diseases or disorders
SG10202101740QA (en) 2015-08-17 2021-04-29 Kura Oncology Inc Methods of treating cancer patients with farnesyl transferase inhibitors
WO2017059385A1 (en) 2015-09-30 2017-04-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
ES2972600T3 (es) 2015-10-30 2024-06-13 Neurocrine Biosciences Inc Sales de diclorhidrato de valbenazina y polimorfos de las mismas
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
EP3394057B1 (en) 2015-12-23 2022-03-30 Neurocrine Biosciences, Inc. Synthetic method for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]lsoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
CN108697663A (zh) 2015-12-31 2018-10-23 科内图斯医药公司 在肝病治疗中使用胱天蛋白酶抑制剂的方法
KR20180095094A (ko) 2016-01-08 2018-08-24 셀진 코포레이션 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
HUE051231T2 (hu) 2016-01-08 2021-03-01 Celgene Corp Antiproliferatív vegyületek, és ezek gyógyszerészeti összetételei és alkalmazásai
CN108712904B (zh) 2016-01-08 2022-08-02 细胞基因公司 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017180589A1 (en) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
AU2017258781C1 (en) 2016-04-29 2022-03-03 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018049080A1 (en) 2016-09-07 2018-03-15 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
BR112019005337A2 (pt) 2016-09-19 2019-08-27 Mei Pharma Inc terapia combinada
JP2019534290A (ja) 2016-11-03 2019-11-28 クラ オンコロジー， インコーポレイテッド 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤
CN110167542A (zh) 2016-11-09 2019-08-23 诺沃梅迪科斯有限公司 1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
US10799503B2 (en) 2016-12-01 2020-10-13 Ignyta, Inc. Methods for the treatment of cancer
US20200078352A1 (en) 2016-12-02 2020-03-12 Neurocrine Biosciences, Inc. Use of Valbenazine for Treating Schizophrenia or Schizoaffective Disorder
CN110769826A (zh) 2017-01-27 2020-02-07 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法
EP3432883B1 (en) 2017-02-21 2021-07-28 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
WO2018175324A1 (en) 2017-03-20 2018-09-27 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
AU2018246138A1 (en) 2017-03-27 2019-08-29 The Regents Of The University Of California Compositions and method of treating cancer
CA3058214A1 (en) 2017-03-29 2018-10-04 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
CN110914276A (zh) 2017-03-29 2020-03-24 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
MA49140A (fr) 2017-05-19 2020-03-25 Nflection Therapeutics Inc Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
US11161845B2 (en) 2017-05-19 2021-11-02 Nflection Therapeutics, Inc. Pyrrolopyridine-aniline compounds for treatment of dermal disorders
AU2018275873A1 (en) 2017-06-01 2019-12-19 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
JP2020528900A (ja) 2017-07-27 2020-10-01 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 体脂肪低減のためのプロスタサイクリン受容体アゴニスト
MY200746A (en) 2017-08-07 2024-01-13 Kura Oncology Inc Methods of treating cancer with farnesyltransferase inhibitors
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20200276209A1 (en) 2017-09-11 2020-09-03 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
MA50175A (fr) 2017-09-21 2021-04-21 Neurocrine Biosciences Inc Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN111836543A (zh) 2017-10-10 2020-10-27 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2019139871A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
AU2019207491A1 (en) 2018-01-10 2020-07-30 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
EP3814327A1 (en) 2018-06-29 2021-05-05 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
AU2019322863A1 (en) 2018-08-15 2021-03-11 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
WO2020072835A1 (en) 2018-10-03 2020-04-09 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
CA3117968A1 (en) 2018-11-01 2020-05-07 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3883554A4 (en) 2018-11-20 2022-11-23 NFlection Therapeutics, Inc. ARYL ANILINE AND HETEROARYL ANILINE COMPOUNDS FOR THE TREATMENT OF NEGAL MARKS
JP7393808B2 (ja) 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン－アニリン化合物
WO2020106303A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
WO2020106306A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
WO2020132071A1 (en) 2018-12-19 2020-06-25 Shy Therapeutics. Llc Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
SG11202106599WA (en) 2018-12-21 2021-07-29 Kura Oncology Inc Therapies for squamous cell carcinomas
US11447468B2 (en) 2019-02-06 2022-09-20 Dice Alpha, Inc. IL-17 ligands and uses thereof
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
TW202100506A (zh) 2019-03-07 2021-01-01 美商柯納特斯製藥公司 半胱天冬酶(caspase)抑制劑及其使用方法
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
SG11202110472WA (en) 2019-03-29 2021-10-28 Kura Oncology Inc Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
TW202102218A (zh) 2019-04-01 2021-01-16 美商庫拉腫瘤技術股份有限公司 以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
WO2021007474A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
EP3997068A1 (en) 2019-07-11 2022-05-18 Cura Therapeutics, LLC Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
WO2021021563A1 (en) 2019-07-26 2021-02-04 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
EP4025184A1 (en) 2019-09-02 2022-07-13 Camurus AB Formulations and treatment methods
MX2022003166A (es) 2019-09-16 2022-06-29 Dice Alpha Inc Moduladores de il-17a y usos de los mismos.
WO2021059023A1 (en) 2019-09-26 2021-04-01 Abionyx Pharma Sa Compounds useful for treating liver diseases
KR20220091488A (ko) 2019-10-01 2022-06-30 몰레큘러 스킨 테라퓨틱스, 인코포레이티드 Klk5/7 이중 억제제로서의 벤족사지논 화합물
JP2021147329A (ja) * 2020-03-16 2021-09-27 株式会社リコー 粒子の製造方法
EP4157271A1 (en) 2020-05-29 2023-04-05 Boulder Bioscience LLC Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
US20230227466A1 (en) 2020-06-18 2023-07-20 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
BR112023002659A2 (pt) 2020-08-14 2023-05-02 Siteone Therapeutics Inc Inibidores de cetona não hidratados de nav1.7 para o tratamento da dor
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
WO2022164997A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
US20240208968A1 (en) 2021-03-10 2024-06-27 Dice Molecules Sv, Inc. Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (en) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
CA3236150A1 (en) 2021-10-22 2023-04-27 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
AU2022399572A1 (en) 2021-11-30 2024-05-02 Kura Oncology, Inc. Macrocyclic compounds having farnesyltransferase inhibitory activity
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
US11981694B2 (en) 2022-01-03 2024-05-14 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
CN114404663A (zh) * 2022-01-07 2022-04-29 浙江瑞谷生物科技有限公司 一种具有炎症缓解特性的骨修复材料及其制备方法
CN114404664A (zh) * 2022-02-17 2022-04-29 浙江瑞谷生物科技有限公司 一种具备长效缓释的骨修复支架材料及其制备方法及应用
WO2023192817A1 (en) 2022-03-28 2023-10-05 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
WO2023192904A1 (en) 2022-03-30 2023-10-05 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
WO2023201282A1 (en) 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Novel gspt1 compounds and methods of use of the novel compounds
WO2023201348A1 (en) 2022-04-15 2023-10-19 Celgene Corporation Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2023215781A1 (en) 2022-05-05 2023-11-09 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
US20240158370A1 (en) 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
WO2024073473A1 (en) 2022-09-30 2024-04-04 Boulder Bioscience Llc Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
US20240139187A1 (en) 2022-10-12 2024-05-02 The Children's Medical Center Corporation Selective hypothalamus permeable hdac6 inhibitors for treatment of leptin-resistant obesity
WO2024086246A2 (en) 2022-10-18 2024-04-25 Eluciderm Inc. 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
US20240174695A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Bicyclic Heteroaryl Compounds
WO2024092037A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing pyridone compounds
WO2024092043A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing pyridine compounds
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
DE3678308D1 (de) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
GB8609537D0 (en) * 1986-04-18 1986-05-21 Ici Plc Polyesters
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
DE69101291T2 (de) 1990-08-30 1994-07-07 Senju Pharma Co Zusammensetzung zur kontrollierten Abgabe von Medikamenten.
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
ATE188375T1 (de) 1992-11-17 2000-01-15 Yoshitomi Pharmaceutical Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
EP0779806B2 (en) * 1994-09-09 2008-04-16 Takeda Pharmaceutical Company Limited Sustained release preparation containing metal salt of a peptide
AU3533395A (en) 1994-09-30 1996-04-26 Takeda Chemical Industries Ltd. Oral sustained-release preparation

Also Published As

Publication number Publication date
JP4361144B2 (ja) 2009-11-11
PT839525E (pt) 2004-10-29
EP0839525B1 (en) 2004-08-04
CA2219698A1 (en) 1998-04-30
CA2219698C (en) 2007-09-04
ES2221019T3 (es) 2004-12-16
US6113943A (en) 2000-09-05
DE69730093T2 (de) 2006-07-20
US6699500B2 (en) 2004-03-02
DE69730093D1 (de) 2004-09-09
JPH10182496A (ja) 1998-07-07
ATE272394T1 (de) 2004-08-15
US20020031545A1 (en) 2002-03-14
EP0839525A1 (en) 1998-05-06

Similar Documents

Publication Publication Date Title
DK0839525T3 (da) Præparat med forlænget frigivelse
ATE220541T1 (de) Feste wirkstoff-zubereitungen
CY1117889T1 (el) Πολυμερες γαλακτικου οξεος και διεργασια για την παραγωγη αυτου
NO995794L (no) Farmasoeytisk preparat inneholdende "Lactobacillus casei rhamnosus"
OA09760A (fr) "Conjugués de protéine et de polyéthylène glycol".
NO884474L (no) Implanterbart, biologisk nedbrytbart virkestoff-frigjoeringssystem.
MA25875A1 (fr) Nouveaux derives de l'acide aminodicarboxylique presentant des proprietes pharmaceutiques.
ATE58292T1 (de) L-dopa enthaltendes arzneimittel.
NO913136D0 (no) Preparat for oeyedraaper.
FR2601259B1 (fr) Nouvelles compositions tensio-actives a base d'esters phosphoriques leur procede de preparation et leur application a la formulation de matieres actives.
EA199900751A1 (ru) Фармацевтическая композиция, содержащая лиофилизированные липосомы, включающие инкапсулированный активный ингредиент, практически нерастворимый в воде, и способ получения композиции
DE68902531D1 (de) Dispergierbare zubereitung.
PT89055A (pt) Processo para a preparacao de um sistema de administracao de libertacao sustida para bloqueadores de canal de calcio a base de di-hidropiridinas substituidas
ITRM930291A0 (it) Procedimento per la preparazione di biopolimeri iodurati con attivita'disinfettante e cicatrizzante, e biopolimeri iodurati cosi' ottenuti.
DE69213183D1 (de) N'-Cyanomethylethylendiamin-N,N'-Diessigsäure, ihre Salze und ihre Herstellung
DE69521122T2 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
IT1241631B (it) "n,n'-ditrimetossibenzoilpiperazine 2-sostituite, procedimento per la loro preparazione e composizioni terapeutiche che le contengono
ATE83668T1 (de) Pflaster zur transdermalen anwendung.
NO880230D0 (no) Peroralt preparat med forsinket frigjoering.
IT1232917B (it) Procedimento per la fabbricazione di microsfere tramite reticolazionedi proteine, microsfere cosi' ottenute e loro impieghi
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
IT1282289B1 (it) 17-idrossiimminoalchil e 17-idrossiimminometilalchenil ciclopentaperidrofenantreni attivi sul sistema cardiovascolare,
FR2716460B1 (fr) Modèle animal de la maladie d'Alzheimer, préparation et utilisations.
IT1243702B (it) Composti ad attivita' nootropa, procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2680369B1 (fr) Derives d'hemoglobine humaine, leur procede de preparation, produits en derivant et utilisation de ces derives et produits.